Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Compass Therapeutics Inc.

Healthcare US CMPX

2.06USD
-0.04(1.90%)

Last update at 2026-06-23T20:13:00Z

Day Range

2.042.11
LowHigh

52 Week Range

1.676.88
LowHigh

Fundamentals

  • Previous Close 2.10
  • Market Cap943.66M
  • Volume3082420
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-72.56300M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -66.48900M -49.37500M -42.49400M -39.22500M -82.18100M
Minority interest - - - - -
Net income -66.48900M -49.37500M -42.49400M -36.79500M -82.55100M
Selling general administrative 16.87M 15.13M 12.24M 11.66M 10.93M
Selling and marketing expenses - - 11.04M - -
Gross profit - 0.85M -1.89000M - -
Reconciled depreciation 1.47M 1.75M 1.89M 1.90M 1.62M
Ebit - -56.62500M -50.36300M -41.65500M -81.88200M
Ebitda -72.83900M -54.87200M -48.47300M -37.39100M -29.61100M
Depreciation and amortization - 1.75M 1.89M 4.26M 52.27M
Non operating income net other - - - 2.43M -0.29900M
Operating income -72.83900M -56.62500M -50.36300M -41.65500M -81.88200M
Other operating expenses - 57.48M 50.36M 41.66M 31.26M
Interest expense - - - 2.36M 0.37M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 6.40M 7.30M 7.87M 2.36M 0.03M
Net interest income 6.40M 7.30M 7.87M 2.36M -0.34100M
Extraordinary items - - - - -
Non recurring - - - - -50.61800M
Other items - - - - -
Income tax expense - - - -2.43000M 0.37M
Total revenue 0.00000M 0.85M 0.00000M 0.00000M 0.00000M
Total operating expenses 72.84M 57.48M 50.36M 41.66M 31.26M
Cost of revenue - - 1.89M - -
Total other income expense net 6.35M 7.25M 7.87M 2.43M -0.29900M
Discontinued operations - - - - -
Net income from continuing ops -66.48900M -49.37500M -42.49400M -39.22500M -82.18100M
Net income applicable to common shares - - - -39.22500M -82.18100M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 219.59M 140.40M 156.88M 199.65M 153.76M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.91M 6.03M 1.42M 8.18M 2.59M
Total liab 22.80M 15.17M 8.34M 18.01M 13.68M
Total stockholder equity 196.79M 125.23M 148.54M 181.64M 140.08M
Deferred long term liab - - - - -
Other current liab 11.38M 6.29M 2.51M 11.69M 8.78M
Common stock 0.02M 0.01M 0.01M 0.01M 0.01000M
Capital stock 0.02M 0.01M 0.01M 0.01M 0.01000M
Retained earnings -431.17200M -364.68300M -315.30800M -272.81400M -233.58900M
Other liab - - - - -
Good will - - - - -
Other assets - - - 0.32M 0.32M
Cash 30.64M 43.48M 24.23M 34.95M 144.51M
Cash and equivalents - - - - -
Total current liabilities 13.97M 8.87M 7.80M 16.17M 10.63M
Current deferred revenue - - - - -
Net debt -20.81400M -36.84900M -22.49500M -32.01100M -140.47700M
Short term debt 1.00M 0.34M 1.20M 1.10M 0.99M
Short long term debt - - - - -
Short long term debt total 9.83M 6.63M 1.73M 2.94M 4.04M
Other stockholder equity 627.66M 489.69M 463.80M 454.74M 373.66M
Property plant equipment - - - 1.57M 6.33M
Total current assets 209.82M 132.75M 153.88M 194.79M 147.10M
Long term investments - - - - -
Net tangible assets - - - 181.64M 140.08M
Short term investments 178.26M 83.24M 128.23M 151.66M -
Net receivables - - - 0.32M -
Long term debt - - - - -
Inventory - - - - -
Accounts payable 1.58M 2.25M 4.09M 3.38M 0.87M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.28M 0.21M 0.04M -0.30200M -
Additional paid in capital - - - - -
Common stock total equity - - - 0.01M 0.01000M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -272.81400M -233.58900M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.57M 0.57M 0.32M 0.32M 0.32M
Deferred long term asset charges - - - - -
Non current assets total 9.77M 7.65M 2.99M 4.85M 6.65M
Capital lease obligations 9.83M 6.63M 1.73M 2.94M 4.04M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -93.28100M 46.77M 26.96M -151.16400M -1.77000M
Change to liabilities - - - 5.43M -0.19400M
Total cashflows from investing activities -93.30600M 46.77M 26.96M -151.20000M -1.77000M
Net borrowings - - - - -9.37500M
Total cash from financing activities 129.61M 17.34M 2.94M 75.76M 118.61M
Change to operating activities - - - -3.77800M 6.44M
Net income -66.48900M -49.37500M -42.49400M -39.22500M -82.18100M
Change in cash -12.84000M 19.25M -10.71800M -109.56800M 97.17M
Begin period cash flow 44.05M 24.23M 34.95M 144.51M 47.34M
End period cash flow 31.21M 43.48M 24.23M 34.95M 144.51M
Total cash from operating activities -49.14300M -44.85500M -40.61800M -34.12500M -19.66600M
Issuance of capital stock 138.00M 18.11M 3.13M 76.24M 128.27M
Depreciation -1.39700M 1.75M 1.89M 1.90M 1.62M
Other cashflows from investing activities - - 0.03M 0.18M -0.20200M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - - - -
Sale purchase of stock - - -0.00016M 75.76M 127.99M
Other cashflows from financing activities 129.61M -0.77500M -0.15900M -0.48000M -0.28100M
Change to netincome - - - 5.26M 54.65M
Capital expenditures 0.03M 0.04M 0.03M 0.21M 1.57M
Change receivables - - - - -
Cash flows other operating - - - -6.37200M 51.10M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - -109.56800M 97.17M
Change in working capital 9.18M -4.14200M -2.90800M -1.26300M 6.25M
Stock based compensation 8.37M 8.56M 6.12M 5.33M 4.03M
Other non cash items 10.38M -1.65100M 5.97M -0.87100M 0.04M
Free cash flow -49.16800M -44.89900M -40.64800M -34.33700M -21.23400M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CMPX
Compass Therapeutics Inc.		 -0.04 1.90% 2.06 - - 269.28 4.79 109.28 -8.9177
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Compass Therapeutics Inc.

80 Guest Street, Boston, MA, United States, 02135

Key Executives

Name Title Year Born
Dr. Thomas J. Schuetz M.D., Ph.D. Co-Founder, CEO & Director 1961
Dr. Vered Bisker-Leib MBA, Ph.D. Pres & COO 1971
Mr. Neil L. Lerner CPA VP of Fin. 1967
Mr. Jonathan Anderman J.D. VP, Head of Legal & Corp. Sec. NA
Anna Gifford Communications Mang. NA
Dr. Peter F. Moesta Ph.D. Interim Head of CMC NA
Dr. Vered Bisker-Leib M.D., MBA, Ph.D. Chief Executive Officer 1972
Dr. Thomas J. Schuetz M.D., Ph.D. Co-Founder, President of Research & Development and Vice Chair 1961
Mr. Neil L. Lerner CPA Vice President of Finance 1967
Mr. Jonathan Anderman J.D. VP, Head of Legal & Corporate Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.